20231-36-1

Upstream product

• 76-83-5 trityl chloride 
• 3396-99-4 methyl α-D-galactopyranoside 
• 86172-85-2 methyl 3,6-di-O-trityl-α-D-galactopyranoside 
• 86172-84-1 (2R,3R,4S,5R,6S)-6-Methoxy-5-trityloxy-2-trityloxymethyl-tetrahydro-pyran-3,4-diol 
• 53685-07-7 Methyl 3,4-O-isopropylidene-6-O-triphenylmethyl-α-D-galactopyranoside 
• 1824-94-8 methyl beta-D-galactopyranoside 
• 87591-35-3 Methyl 2,3,4-tri-O-acetyl-6-O-trityl-β-D-galactopyranoside 
• 617-04-9 (2R,3S,4S,5S,6S)-2-(hydroxymethyl)-6-methoxytetrahydro-2H-pyran-3,4,5-triol 
• 86172-79-4 (2S,3S,4S,5R,6R)-2-Methoxy-4-trityloxy-6-trityloxymethyl-tetrahydro-pyran-3,5-diol 
• 86172-80-7 (2S,3S,4R,5S,6R)-2-Methoxy-5-trityloxy-6-trityloxymethyl-tetrahydro-pyran-3,4-diol 
• 86172-78-3 (2R,3S,4S,5S,6S)-6-Methoxy-5-trityloxy-2-trityloxymethyl-tetrahydro-pyran-3,4-diol 
• 530-26-7 D-Mannose 

Downstream Products

• 18685-19-3 methyl 2,3,4-tri-O-benzyl-6-O-trityl-α-D-galactopyranoside 
• 38982-56-8 methyl 2,3,4-tri-O-acetyl-6-O-trityl-α-D-galactopyranoside 
• 808148-61-0 Pent-4-enoic acid (2R,3S,4S,5R,6S)-6-methoxy-4,5-bis-pent-4-enoyloxy-2-trityloxymethyl-tetrahydro-pyran-3-yl ester 
• 799269-19-5 methyl 6-O-trityl-2,3,4-tri-O-(p-toluoyl)-α-D-galactopyranoside 
• 794525-42-1 methyl 2,3,4-tri-O-(p-toluoyl)-α-D-galactopyranoside 
• 7432-72-6 Methyl 2,3,4-tri-O-acetyl-α-D-galactopyranoside 
• 76-84-6 triphenylmethyl alcohol 
• 4356-80-3 methyl 2,3,4-tri-O-benzyl-α-D-galactopyranoside 
• 164323-13-1 (2S,3R,4S,5R,6S)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2H-pyran-2-carboxylic acid 
• 83075-41-6 methyl (methyl 2,3,4-tri-O-benzyl-α-D-galactopyranosid)uronate 
• 5155-54-4 methyl (methyl α-D-galacturonopyranoside)uronate 
• 71756-38-2 methyl 2,3-di-O-benzyl-6-O-trityl-α-D-galactopyranoside 
• 31505-55-2 methyl 2,3-di-O-benzoyl-6-O-triphenylmethyl-α-D-galactopyranoside 
• 1261294-42-1 methyl 6-S-acetyl-2,3,4-tri-O-benzyl-6-deoxy-α-D-galactopyranoside 

Relevant academic research and scientific papers

USE OF MANNOSE 6 PHOSPHATE AND MODIFICATIONS THEREOF FOR MEMORY ENHANCEMENT AND REDUCING MEMORY IMPAIRMENT

Provided are compositions and methods for memory enhancement, including recovery of memory impairment. The compositions and methods relate to mannose-6-phosphate and derivatives of mannose-6-phosphate. The methods relate to administration of M6P or derivatives thereof to individuals in whom memory enhancement is desired.

BORON CLUSTER-COUPLED COMPOUND

To provide a novel boron-containing compound which increases intratumorous accumulation and tumor retention, and is efficiently taken into a tumor cell.SOLUTION: The present invention relates to a compound represented by formula (I) in the figure or a salt thereof. [In the formula, X represents a divalent to pentavalent organic group; Y represents a linker structure; R represents a monovalent group comprising boron clusters; and n represents 2, 3, 4 or 5.SELECTED DRAWING: None

USE OF IGF-2 RECEPTOR AGONIST LIGANDS FOR TREATMENT OF ANGELMAN SYNDROME AND AUTISM

Provided are methods for treatment of neurodevelopmental disorders, such as Angelman Syndrome and autism comprising administering to an individual a composition comprising an agonist ligand of IGF -2 receptor. The agonist ligand of IGF-2 receptor may be IGF -2, or mannose-6-phosphate or a derivative thereof. Compositions comprising mannose-6-phosphate derivatives are also disclosed.

A Potent Mimetic of the Siglec-8 Ligand 6’-Sulfo-Sialyl Lewisx

Siglecs are members of the immunoglobulin gene family containing sialic acid binding N-terminal domains. Among them, Siglec-8 is expressed on various cell types of the immune system such as eosinophils, mast cells and weakly on basophils. Cross-linking of Siglec-8 with monoclonal antibodies triggers apoptosis in eosinophils and inhibits degranulation of mast cells, making Siglec-8 a promising target for the treatment of eosinophil- and mast cell-associated diseases such as asthma. The tetrasaccharide 6’-sulfo-sialyl Lewisx has been identified as a specific Siglec-8 ligand in glycan array screening. Here, we describe an extended study enlightening the pharmacophores of 6’-sulfo-sialyl Lewisx and the successful development of a high-affinity mimetic. Retaining the neuraminic acid core, the introduction of a carbocyclic mimetic of the Gal moiety and a sulfonamide substituent in the 9-position gave a 20-fold improved binding affinity. Finally, the residence time, which usually is the Achilles tendon of carbohydrate/lectin interactions, could be improved.

MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE

The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).

Visible-Light-Mediated, Chemo- and Stereoselective Radical Process for the Synthesis of C-Glycoamino Acids

An approach for efficient synthesis of C-glycosyl amino acids is described. Different from typical photoredox-catalyzed reactions of imines, the new process follows a pathway in which α-imino esters serve as electrophiles in chemoselective addition reactions with nucleophilic glycosyl radicals. The process is highlighted by the mild nature of the reaction conditions, the highly stereoselectivity attending C-C bond formation, and its applicability to C-glycosylations using both armed and disarmed pentose and hexose derivatives.

From d-to l-Monosaccharide Derivatives via Photodecarboxylation-Alkylation

Photodecarboxylation-alkylation of conformationally locked monosaccharides leads to inversion of stereochemistry at C5. This allows the synthesis of l-sugars from their readily available d-counterparts. Via this strategy, methyl l-guloside was synthesized from methyl d-mannoside in 21% yield over six steps.

Study of Uridine 5′-Diphosphate (UDP)-Galactopyranose Mutase Using UDP-5-Fluorogalactopyranose as a Probe: Incubation Results and Mechanistic Implications

Uridine 5′-diphosphate-5-fluorogalactopyranose (UDP-5F-Galp, 7) was synthesized, and its effect on UDP-Galp mutase (UGM) was investigated. UGM facilitated the hydrolysis of 7 to yield UDP and 5-oxogalactose (24), but no 11 was detected. 19F NMR and trapping experiments demonstrated that the reaction involves the initial formation of a substrate-cofactor adduct followed by decomposition of the resulting C5 gem-fluorohydrin to generate a 5-oxo intermediate (10). The results support the current mechanistic proposal for UGM and suggest new directions for designing mechanism-based inhibitors.

Synthesis of mannoheptose derivatives and their evaluation as inhibitors of the lectin LecB from the opportunistic pathogen Pseudomonas aeruginosa

Abstract Biofilm formation and chronic infections with Pseudomonas aeruginosa depend on lectins produced by the bacterium. The bacterial C-type lectin LecB binds to the two monosaccharides l-fucose and d-mannose and conjugates thereof. Previously, d-manno

Evaluation of potential Myt1 kinase inhibitors by TR-FRET based binding assay

In the human cell cycle, the Myt1 kinase is a crucial regulator of the G2/M transition. Because this membrane-associated kinase is hard to obtain and assay, there is a distinct lack of data so far. Here we report the derivatization of a glycoglycerolipid which was shown previously to be active in a Myt1 activity assay. These compounds were tested in a binding assay together with a set of common kinase inhibitors against a full-length Myt1 expressed in a human cell line. Dasatinib exhibited nanomolar affinity whereas broad coverage inhibitors such as sunitinib and staurosporine derivatives did not show any effect. We also carried out docking studies for the most potent compounds allowing further insights into the inhibitor interaction of this kinase. The glycoglycerolipids showed no significant effects in the binding assay, endorsing the idea of a mechanism of action distant from the active site.